Cargando…
Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies
Following our recent observation that alterations of the Natural Killer (NK) cell compartment in the presence of BCR-ABL-induced myeloproliferation fail to revert under targeted therapy, we discuss by what mechanisms oncogenic molecular pathways and their pharmacological inhibition may interfere wit...
Autor principal: | Rossig, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382876/ https://www.ncbi.nlm.nih.gov/pubmed/22737614 http://dx.doi.org/10.4161/onci.18401 |
Ejemplares similares
-
Extending the chimeric receptor-based T-cell targeting strategy to solid tumors
por: Rossig, Claudia
Publicado: (2013) -
Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
por: Yang, Yan, et al.
Publicado: (2013) -
Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
por: Rudqvist, Nils-Petter, et al.
Publicado: (2023) -
Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019) -
Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)